Abstract
Session presented on Saturday, July 23, 2016 and Sunday, July 24, 2016:
Purpose: The purpose of this study was to perform comparative analysis of practice guidelines and current evidence for the management of hyperglycemia in hospitalized patients.
Methods: An integrative literature review was conducted using Cochrane, CINAHL Plus, PubMed and the National Guideline Clearing House. Key words searched included hyperglycemia, inpatient diabetes, pre-operative, surgical, NPO, hospitalized, Type 1, Type 2 diabetes, Nothing by mouth, Adult, basal bolus, Hypoglycemia, management, insulin, rabbit two trial.
Results: Hyperglycemia and hypoglycemia are both serious and costly health care problems in hospitalized patients. The risk for sepsis, pneumonia, and wound infections increase with hyperglycemia; however, fear of hypoglycemia, is a leading barrier to improving glycemic management in the hospital setting (Umpierrez et al, 2007, 2012). Individuals with Type 1 diabetes lack endogenous insulin, thus requiring treatment with basal (once daily --glargine or detemir) or twice daily--Neutral Protamine Hagedorn (NPH) bolus correction (rapid acting insulin analog (aspart, lispro, glulisine,) or regular) insulin regimens to avoid severe hyperglycemia and diabetic ketoacidosis. Patients with type 2 diabetes, receiving insulin therapy before admission, are at risk for severe hyperglycemia, when insulin is discontinued. Peer-reviewed literature supported practice guidelines for all patients using insulin before hospital admission. Guidelines recommend continuing basal scheduled subcutaneous (SC) insulin with modifications, to maintain target glucose levels. Additionally, evidence supported current recommendations for patients with Type 1 diabetes undergoing surgical intervention to receive either continuous insulin infusion (CII) or subcutaneous basal insulin with correction insulin as required to prevent hyperglycemia during the perioperative period (Umpierrez, et al, 2012).
Conclusion: A basal insulin plus bolus correction regimen is the preferred treatment for non-critically ill patients, not eating or drinking. Blood glucose should be monitored every 4-6 hours while nothing by mouth, and corrected with short-acting insulin as needed (American Diabetes Association, 2016).
Sigma Membership
Non-member
Type
Poster
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
NPO, Hyperglycemia, Inpatient Insulin
Recommended Citation
Emery, Joyce Elaine and Mendoza, Martina, "Should insulin be withheld when nothing by mouth is ordered in patients who require insulin?" (2016). INRC (Congress). 18.
https://www.sigmarepository.org/inrc/2016/posters_2016/18
Conference Name
27th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Cape Town, South Africa
Conference Year
2016
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Should insulin be withheld when nothing by mouth is ordered in patients who require insulin?
Cape Town, South Africa
Session presented on Saturday, July 23, 2016 and Sunday, July 24, 2016:
Purpose: The purpose of this study was to perform comparative analysis of practice guidelines and current evidence for the management of hyperglycemia in hospitalized patients.
Methods: An integrative literature review was conducted using Cochrane, CINAHL Plus, PubMed and the National Guideline Clearing House. Key words searched included hyperglycemia, inpatient diabetes, pre-operative, surgical, NPO, hospitalized, Type 1, Type 2 diabetes, Nothing by mouth, Adult, basal bolus, Hypoglycemia, management, insulin, rabbit two trial.
Results: Hyperglycemia and hypoglycemia are both serious and costly health care problems in hospitalized patients. The risk for sepsis, pneumonia, and wound infections increase with hyperglycemia; however, fear of hypoglycemia, is a leading barrier to improving glycemic management in the hospital setting (Umpierrez et al, 2007, 2012). Individuals with Type 1 diabetes lack endogenous insulin, thus requiring treatment with basal (once daily --glargine or detemir) or twice daily--Neutral Protamine Hagedorn (NPH) bolus correction (rapid acting insulin analog (aspart, lispro, glulisine,) or regular) insulin regimens to avoid severe hyperglycemia and diabetic ketoacidosis. Patients with type 2 diabetes, receiving insulin therapy before admission, are at risk for severe hyperglycemia, when insulin is discontinued. Peer-reviewed literature supported practice guidelines for all patients using insulin before hospital admission. Guidelines recommend continuing basal scheduled subcutaneous (SC) insulin with modifications, to maintain target glucose levels. Additionally, evidence supported current recommendations for patients with Type 1 diabetes undergoing surgical intervention to receive either continuous insulin infusion (CII) or subcutaneous basal insulin with correction insulin as required to prevent hyperglycemia during the perioperative period (Umpierrez, et al, 2012).
Conclusion: A basal insulin plus bolus correction regimen is the preferred treatment for non-critically ill patients, not eating or drinking. Blood glucose should be monitored every 4-6 hours while nothing by mouth, and corrected with short-acting insulin as needed (American Diabetes Association, 2016).